文献速递临床微生物分子诊断

AtbFinder诊断测试系统改善囊性纤维化患者抗生素治疗选择

AtbFinder Diagnostic Test System Improves Optimal Selection of Antibiotic Therapy in Persons with Cystic Fibrosis.
PubMed 文献 · J Clin Microbiol · 2023-01-05

该开放标签、单臂、研究者发起的临床研究纳入35例囊性纤维化患者(33例慢性铜绿假单胞菌定植),评估基于AtbFinder选择的抗生素治疗的疗效。结果显示AtbFinder选择的抗生素使81.8%的后续培养清除铜绿假单胞菌,年加重次数从1.21次降至0,FEV1占预计值百分比从基线最高提升28.4%,全身抗生素疗程从355次减少至178次。

要点

  • AtbFinder模拟组织可达到浓度及多菌种生物膜条件选择抗生素。
  • AtbFinder选药后81.8%后续培养清除铜绿假单胞菌。
  • 年加重次数从1.21次降至0,全身抗生素疗程从355次减至178次。

核心结论

  • 基于AtbFinder选择的抗生素方案优于常规药敏试验选择的方案。

研究设计与样本

  • 开放标签、单臂、研究者发起的临床研究,纳入35例囊性纤维化患者(33例慢性铜绿假单胞菌定植)。

主要发现

  • AtbFinder选药后81.8%的后续培养清除铜绿假单胞菌。
  • 年加重次数从1.21次/患者/年降至0。
  • FEV1占预计值百分比从基线最高提升28.4%。
  • 全身抗生素疗程从355次减少至178次。

临床怎么用

  • 对于囊性纤维化合并慢性铜绿假单胞菌感染患者,可考虑采用AtbFinder指导抗生素选择以改善疗效。

局限性

  • 本研究为开放标签、单臂设计,非随机对照,样本量较小(35例),结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cystic fibrosis (CF) is characterized by mutations of CFTR that lead to increased viscous secretions, bacterial colonization, and recurrent infections. Chronic Pseudomonas aeruginosa infection in persons with CF is associated with progressive and accelerated lung function decline despite aggressive antibiotic treatment. We report the management of respiratory infections in persons with CF with antibiotic therapy that was based on the recommendations of AtbFinder, a novel, rapid, culture-based diagnostic test system that employs a novel paradigm of antibiotic selection. AtbFinder mimics bacterial interactions with antibiotics at concentrations that can be achieved in affected tissues or organs and models conditions of interbacterial interactions within polymicrobial biofilms. This open-label, single-arm, investigator-initiated clinical study was designed to identify the efficacy of antibiotics selected using AtbFinder in persons with CF. Microbiological and clinical parameters were assessed following the change of antibiotic therapy to antibiotics selected with AtbFinder between January 2016 and December 2018 and retrospectively compared with clinical data collected between January 2013 and December 2015. We enrolled 35 persons with CF (33 with chronic P. aeruginosa colonization). Antibiotics selected using AtbFinder resulted in clearance of P. aeruginosa in 81.8% of subsequent cultures, decreased pulmonary exacerbations from 1.21 per patient per annum to 0, and an increase in predicted percent predicted forced expiratory volume in 1 s up to 28.4% from baseline. The number of systemic antibiotic courses used in patients after switching to the AtbFinder-selected therapy was reduced from 355 to 178. These findings describe the superiority of antibiotic regimens selected with AtbFinder compared with routine antimicrobial susceptibility testing.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Tetz G, Kardava K, Vecherkovskaya M, et al. AtbFinder Diagnostic Test System Improves Optimal Selection of Antibiotic Therapy in Persons with Cystic Fibrosis. J Clin Microbiol. 2023. PMID: 36602344. doi:10.1128/jcm.01558-22

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。